Nu-Med Plus annual ebitda
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Nu-Med Plus EBITDA Growth & History (NUMD)
Nu-Med Plus's calculated EBITDA was −$179,900 for fiscal 2022.
View full Nu-Med Plus company overviewNu-Med Plus annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | −$179,900 | $650,180 | — |
| 2021 | 2021-12-31 | −$830,080 | $1.2M | — |
| 2020 | 2020-12-31 | −$2.0M | −$976,819 | — |
| 2019 | 2019-12-31 | −$1.0M | $148,504 | — |
| 2018 | 2018-12-31 | −$1.2M | −$700,592 | — |
| 2017 | 2017-12-31 | −$453,976 | $763,475 | — |
| 2016 | 2016-12-31 | −$1.2M | −$278,122 | — |
| 2015 | 2015-12-31 | −$939,329 | $199,828 | — |
| 2014 | 2014-12-31 | −$1.1M | −$908,716 | — |
| 2013 | 2013-12-31 | −$230,441 | $25,969 | — |
| 2012 | 2012-12-31 | −$256,410 | — | — |
Nu-Med Plus quarterly ebitda
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2022 | 2022-12-31 | −$6,393 | $103,298 | — |
| Q3 2022 | 2022-09-30 | −$58,016 | $57,700 | — |
| Q2 2022 | 2022-06-30 | −$57,853 | $192,721 | — |
| Q1 2022 | 2022-03-31 | −$57,638 | $296,461 | — |
| Q4 2021 | 2021-12-31 | −$109,691 | $378,819 | — |
| Q3 2021 | 2021-09-30 | −$115,716 | $330,994 | — |
| Q2 2021 | 2021-06-30 | −$250,574 | $650,824 | — |
| Q1 2021 | 2021-03-31 | −$354,099 | −$207,834 | — |
| Q4 2020 | 2020-12-31 | −$488,510 | −$285,842 | — |
| Q3 2020 | 2020-09-30 | −$446,710 | −$303,631 | — |
| Q2 2020 | 2020-06-30 | −$901,398 | −$661,034 | — |
| Q1 2020 | 2020-03-31 | −$146,265 | $273,688 | — |
| Q4 2019 | 2019-12-31 | −$202,668 | $129,524 | — |
| Q3 2019 | 2019-09-30 | −$143,079 | $375,409 | — |
| Q2 2019 | 2019-06-30 | −$240,364 | −$75,454 | — |
| Q1 2019 | 2019-03-31 | −$419,953 | −$280,975 | — |
| Q4 2018 | 2018-12-31 | −$332,192 | −$188,036 | — |
| Q3 2018 | 2018-09-30 | −$518,488 | −$384,325 | — |
| Q2 2018 | 2018-06-30 | −$164,910 | −$57,192 | — |
| Q1 2018 | 2018-03-31 | −$138,978 | −$71,039 | — |
| Q4 2017 | 2017-12-31 | −$144,156 | $159,842 | — |
| Q3 2017 | 2017-09-30 | −$134,163 | $552,990 | — |
| Q2 2017 | 2017-06-30 | −$107,718 | $61,583 | — |
| Q1 2017 | 2017-03-31 | −$67,939 | −$10,940 | — |
| Q4 2016 | 2016-12-31 | −$303,998 | −$170,573 | — |
| Q3 2016 | 2016-09-30 | −$687,153 | −$385,640 | — |
| Q2 2016 | 2016-06-30 | −$169,301 | $218,203 | — |
| Q1 2016 | 2016-03-31 | −$56,999 | $59,888 | — |
| Q4 2015 | 2015-12-31 | −$133,425 | $394,701 | — |
| Q3 2015 | 2015-09-30 | −$301,513 | −$64,308 | — |
| Q2 2015 | 2015-06-30 | −$387,504 | −$190,934 | — |
| Q1 2015 | 2015-03-31 | −$116,887 | $60,369 | — |
| Q4 2014 | 2014-12-31 | −$528,126 | −$497,710 | — |
| Q3 2014 | 2014-09-30 | −$237,205 | −$150,205 | — |
| Q2 2014 | 2014-06-30 | −$196,570 | −$163,362 | — |
| Q1 2014 | 2014-03-31 | −$177,256 | −$97,439 | — |
| Q4 2013 | 2013-12-31 | −$30,416 | $79,577 | — |
| Q3 2013 | 2013-09-30 | −$87,000 | — | — |
| Q2 2013 | 2013-06-30 | −$33,208 | — | — |
| Q1 2013 | 2013-03-31 | −$79,817 | — | — |
| Q3 2012 | 2012-09-30 | −$109,993 | — | — |
Nu-Med Plus ebitda trends
Over the last five reported fiscal years, Nu-Med Plus's ebitda increased from −$453,976 to −$179,900, a change of $274,076. The latest reported quarter, Q4 2022, shows −$6,393.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nu-Med Plus filings at SEC.gov ↗